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Abstract
Background: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in
which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent
cytopenias may not meet minimal diagnostic criteria for MDS but an alternate diagnosis is not apparent; the term
idiopathic cytopenia of undetermined significance (ICUS) has been used to describe this state. MDS and AML occur
primarily in older patients who are often treated outside the clinical trial setting. Consequently, our understanding
of the patterns of diagnostic evaluation, management, and outcomes of these patients is limited. Furthermore,
there are few natural history studies of ICUS. To better understand how patients who have MDS, ICUS, or AML are
managed in the routine clinical setting, the Connect MDS/AML Disease Registry, a multicenter, prospective,
observational cohort study of patients newly diagnosed with these conditions has been initiated.
Methods/Design: The Connect MDS/AML Disease Registry will capture diagnosis, risk assessment, treatment, and
outcomes data for approximately 1500 newly diagnosed patients from approximately 150 community and
academic sites in the United States in 4 cohorts: (1) lower-risk MDS (International Prognostic Scoring System [IPSS]
low and intermediate-1 risk), with and without del(5q); (2) higher-risk MDS (IPSS intermediate-2 and high risk); (3)
ICUS; and (4) AML in patients aged ≥ 55 years (excluding acute promyelocytic leukemia). Diagnosis will be
confirmed by central review. Baseline patient characteristics, diagnostic patterns, treatment patterns, clinical
outcomes, health economics outcomes, and patient-reported health-related quality of life will be entered into an
electronic data capture system at enrollment and quarterly for 8 years. A tissue substudy to explore the relationship
between karyotypes, molecular markers, and clinical outcomes will be conducted, and is optional for patients.
Discussion: The Connect MDS/AML Disease Registry will be the first prospective, observational, non-interventional
study in the United States to collect clinical information, patient-reported outcomes, and tissue samples from
patients with MDS, ICUS, or AML receiving multiple therapies. Results from this registry may provide new insights
into the relationship between diagnostic practices, treatment regimens, and outcomes in patients with these
diseases and identify areas for future investigation.
(Continued on next page)
* Correspondence: david_steensma@dfci.harvard.edu
1Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Steensma et al. BMC Cancer  (2016) 16:652 
DOI 10.1186/s12885-016-2710-6
(Continued from previous page)
Trial registration: Connect MDS/AML Disease Registry (NCT01688011). Registered 14 September 2012.
Keywords: Myelodysplastic syndromes, Acute myeloid leukemia, Idiopathic cytopenia of undetermined significance,
Registry, Treatment patterns, Clinical outcomes, Patient-reported outcomes, Biomarkers, Clonal hematopoiesis of
indeterminate potential (CHIP)
Abbreviations: AML, Acute myeloid leukemia; CHIP, Clonal hematopoiesis of indeterminate potential;
EDC, Electronic data capture; FACT-An, Functional Assessment of Cancer Therapy-Anemia; HEOR, Health economics
and outcomes research; HMA, Hypomethylating agent; HRQOL, Health-related quality of life; ICUS, Idiopathic
cytopenia of undetermined significance; Int-1, Intermediate 1 risk; Int-2, Intermediate 2 risk; IPSS, International
Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring System; MDS, Myelodysplastic
syndromes; NCCN, National Comprehensive Cancer Network; PRO, Patient-reported outcome; SSC, Scientific steering
committee; UBC, United BioSource Corporation
Background
Myelodysplastic syndromes (MDS) are a heteroge-
neous group of clonal myeloid malignancies charac-
terized by ineffective hematopoiesis, peripheral blood
cytopenias, and a propensity to transform into acute
myeloid leukemia (AML) [1–3]. AML, which can arise
de novo or secondary to prior myeloproliferative neo-
plasms or MDS, is defined by ≥ 20 % myeloid blasts
in the marrow or blood, or the presence of specific
cytogenetic abnormalities [4]. In the elderly, AML
and MDS tend to have similar presentation with cyto-
penias and associated clinical manifestations of these
cytopenias, including infection, bleeding, and the poor
oxygen-carrying capacity characteristic of anemia [2, 5].
MDS and AML are classified using World Health
Organization criteria based on blood counts, morpho-
logical criteria, and cytogenetic data [6, 7]. Some
patients with persistent cytopenia(s) may not meet
the minimal diagnostic criteria for MDS, yet no other
diagnosis is apparent [8]. These patients are said to
have idiopathic cytopenia of undetermined signifi-
cance (ICUS) [8]. Unlike monoclonal gammopathy of
undetermined significance, a clonal state that is a
precursor to multiple myeloma or other plasma cell
neoplasms, ICUS is not a clonal disorder by defin-
ition; if a clonal mutation in a myeloid neoplasia–
associated gene is present, the patient is instead said
to have clonal hematopoiesis of indeterminate poten-
tial (CHIP) [9]. Although some patients with ICUS
may eventually develop MDS or AML, the proportion
that do is unknown as there is a lack of natural his-
tory studies of this condition [9–11].
Although MDS, ICUS, and AML can occur at any age,
they are most common in older patients. In the United
States, the median age at diagnosis of MDS and AML is
approximately 70 years, although exact estimates vary
[12, 13]. Less is known regarding the epidemiology of
ICUS, although the median age reported in the few
existing studies ranges from 61 to 69 years [11].
Because of varying criteria for diagnosis, omission of
MDS in cancer registries until recently, and incomplete
evaluation of many elderly patients with mild cytopenias,
it has been difficult to accurately assess the incidence
and prevalence of MDS [2, 14, 15]. Based on US Medi-
care claims data, it is estimated there may be ≥ 75 new
cases of MDS per 100,000 people aged ≥ 65 annually in
the United States, making MDS one of the most com-
mon hematologic malignancies [2, 15, 16]. AML is the
most common acute leukemia in the United States, with
approximately 20,000 new cases annually [12]. The inci-
dence of ICUS remains unclear.
MDS treatment recommendations are based on indi-
vidual patient characteristics and disease risk, which can
be assessed using one of several prognostic scoring sys-
tems [17], such as the widely used 1997 International
Prognostic Scoring System (IPSS). Patients with asymp-
tomatic lower-risk (IPSS low/intermediate-1 [Int-1] risk)
MDS are often monitored using a “watch and wait”
approach, without specific therapy [18]. Patients with
symptomatic lower-risk MDS are generally treated
with low-intensity therapies such as supportive care
(ie, transfusion support or erythropoiesis-stimulating
agents) or lenalidomide, whereas those with higher-risk
(IPSS int-2/high risk) MDS are often treated more inten-
sively with disease-modifying therapy, including the DNA
hypomethylating agents (HMAs) azacitidine or decitabine,
cytotoxic chemotherapy, or allogeneic stem cell trans-
plant [17]. However, except in younger, healthier pa-
tients who can potentially be cured with allogeneic
stem cell transplant, MDS therapy is largely palliative,
and many questions remain regarding the optimal man-
agement of patients with MDS [2].
The IPSS was revised (IPSS-R) in 2012 to improve risk
stratification [19]. The IPSS-R includes more parameters
than the IPSS and adds a fifth intermediate risk category
that doesn’t fall cleanly into lower or higher risk, which
may make this fifth category challenging for physicians
to incorporate into routine clinical practice [2, 17, 19].
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Additionally, a modification of the IPSS-R that incorpo-
rates mutational data was recently proposed, providing
enhanced predictive power in patients with MDS across
the course of the disease, regardless of treatment history
[20]. Although the IPSS-R was designed to improve
prognostic classification, prospective studies detailing
how the IPSS-R is being used in clinical practice and
what effect this has on real-world treatment decisions
and outcomes have yet to be conducted.
AML treatment recommendations are largely based on
age, with intensive chemotherapy and transplant gener-
ally reserved for patients less than 70 years of age [5].
Patient fitness is also taken into account when determin-
ing eligibility for intensive treatment and transplant [21],
and this often requires clinicians to make difficult judg-
ments. Treatment options for older patients with AML
who are not eligible for intensive treatment are limited
and, outside of a clinical trial, typically include HMAs,
low-dose cytarabine, and supportive care [5, 12]. Out-
comes in older patients with AML remain dismal, with a
5-year survival rate of 5 % in patients > 65 years of age
in the United States, which lags behind the 38 % 5-year
survival rate in patients < 65 years of age [5, 12].
Although various guidelines exist for the treatment of
patients with MDS and AML, such as those of the Na-
tional Comprehensive Cancer Network (NCCN) or the
European LeukemiaNet [17, 21–23], patterns of treat-
ment and clinical outcomes in patients with MDS or
AML outside of clinical trials are poorly characterized.
Treatment decision-making can be complex and challen-
ging, especially for elderly patients who may have co-
morbid conditions and poor performance status [5, 24].
Moreover, a recent survey of physicians treating patients
with MDS indicated that they frequently did not adhere
to NCCN guidelines for length of treatment [25].
There are currently no specific treatments for ICUS
other than addressing factors contributing to cytopenias
when identified, and it is recommended that patients be
monitored with regular follow-up hematologic assess-
ments to surveil for progression to an overt myeloid
neoplasm [11]. No large observational studies have been
performed to date to inform best clinical practices and
to understand long-term outcomes in patients with
ICUS [9, 11].
There are currently gaps in the knowledge of MDS,
ICUS, and AML with regard to diagnostic trends, prog-
nostic categorization, long-term treatment patterns, and
clinical and health-related quality of life (HRQOL) out-
comes. Moreover, data from patients enrolled in clinical
trials may not apply to patients treated outside of a trial,
such as those who may lack sufficient resources to travel
to participate in a trial or who are excluded from such
trials due to poor performance status and multiple co-
morbidities [5, 26, 27]. The Connect MDS/AML Disease
Registry (Clinicaltrials.gov Identifier NCT01688011) is a
multicenter, prospective, observational cohort study of
patients with newly diagnosed MDS, ICUS, or AML in
the United States. This registry aims to acquire robust
data that will be representative of these patient popula-
tions in the United States. It is designed to capture pat-
terns of diagnosis, risk assessment, and treatment of
MDS, ICUS, and AML as well as clinical and patient-
reported outcomes (PROs). This registry represents an
opportunity to document key variables affecting treat-
ment decisions and clinical outcomes in MDS, ICUS,
and AML and to provide new insight into these hetero-
geneous diseases. The primary objectives of the disease
registry are to:
1. Describe the current and evolving patterns of
diagnosis, prognosis, evaluation, treatment, clinical
monitoring, and outcome measures;
2. Compare actual clinical practice patterns in both
community and academic settings with existing
management guidelines (eg, NCCN);
3. Describe treatment patterns and the associated
short- and long-term outcomes in non-del(5q)
patients and in del(5q) patients with or without
additional cytogenetic abnormalities, including
response, safety, disease progression, and survival;
4. Summarize PROs (eg, HRQOL) and health
economics and outcomes research (HEOR) and their
association with patient characteristics, treatment
regimens, and clinical outcomes.
The disease registry study plan also includes a correla-
tive substudy designed to identify molecular markers
and evaluate their potential impact on prognostication
and/or treatment outcomes.
Methods/Design
The Connect MDS/AML Disease Registry was designed
collaboratively by 2 scientific steering committees (SSCs)
composed of academic and community-based practi-
tioners in MDS (SSC-MDS) and AML (SSC-AML) in
partnership with Celgene Corporation. The SSCs include
experts in molecular and correlative research, as well as
HRQOL, and are responsible for managing the study
with guidance and review by Celgene Corporation.
Setting
Patients will be enrolled at approximately 150 sites in
the United States. Hematologists or oncologists experi-
enced in the treatment of MDS, ICUS, or AML express-
ing an interest in participating in the disease registry will
be evaluated as site principal investigators. Study investi-
gators must maintain a practice with enough potential
patients to achieve the quarterly enrollment target, and
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have adequate staff available for coordinating the study
and conducting daily research activities. To best capture
the distribution of routine clinical practice settings in
which patients are typically treated, approximately 70 to
80 % of the sites will be community-based clinics and 20
to 30 % will be academic institutions (defined as affili-
ated with a medical school).
Sample size
Approximately 1500 patients with MDS, ICUS, or AML
will be enrolled into 4 main cohorts (Fig. 1). The sizes of
the cohorts were chosen to ensure adequate representa-
tion to address the critical objectives of the registry. The
first cohort consists of 700 patients with lower-risk
MDS, classified as IPSS low and int-1 risk, and is divided
into subcohorts of patients with del(5q) (n = 250) and
without del(5q) (n = 450). One of the objectives of the
del(5q) cohort is to describe treatment outcomes in
these patients. Currently, the only approved treatment
specific to the del(5q) subgroup is lenalidomide, and ap-
proximately 50 % of patients with del(5q) continue past
3 cycles of therapy. Therefore, the expectation is that
125 patients will be on lenalidomide for more than 3 cycles.
For the 250 del(5q) patients with an expected response rate
of 57 % with a 10-mg dose, based on the MDS-003 and
MDS-004 studies, the 2-sided 95 % confidence interval for
this estimate is 0.51 to 0.63. For the 450 non-del(5q)
patients, based on the MDS-005 study, > 60 % of patients,
or approximately 270 patients, are expected to complete
4 cycles of therapy. With an expected response rate of
27 %, the 2-sided 95 % confidence interval is 0.23 to 0.31
and 122 patients are expected to respond, providing
enough patients to explore predictors of response. The
second cohort consists of patients with higher-risk MDS
Fig. 1 Connect MDS/AML Disease Registry study design. Overview of the study design of the disease registry from enrollment through follow-up.
AML acute myeloid leukemia, APL acute promyelocytic leukemia, BM bone marrow, EQ‐5D‐3L EuroQOL. Group 5‐dimension 3‐level questionnaire,
FACT‐An Functional Assessment of Cancer Therapy‐Anemia, ICUS idiopathic cytopenia of undetermined significance, MDS myelodysplastic
syndromes, PB peripheral blood. aMDS diagnosis refers to the date of initial BM aspirate/biopsies for patients. bAML diagnosis refers to the date
of BM aspirate/biopsies or the date of initial PB sample that led to the suspecte diagnosis. cICUS diagnosis refers to patients with ≥ 6 months’
cytopenia in ≥ 1 myeloid lineage who do not meet the criteria for diagnosis of MDS. dReview of BM aspirate/biopsies reports and cytogenetic
report, PB laboratory results, or other reports that led to diagnosis of MDS or AML. Tissue samples are not reviewed; patients whose diagnosis
and/or risk cannot be confirmed are deemed screen failures
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(n = 200), classified as IPSS int-2 or high risk. Two hun-
dred patients should be an adequate sample size to de-
scribe diagnostic patterns and treatment effectiveness in
this cohort. The third cohort consists of patients with
ICUS (n = 200). No sample size estimation was done for
this group since it is viewed as exploratory. The fourth
cohort consists of patients with AML aged ≥ 55 years (n =
400). The age criterion was selected for patients with
AML because of the complexities of treating older patients
due to age-related comorbidities and increased vulnerabil-
ity to therapeutic toxicities [5, 21, 26]. A sample size of
400 patients should be sufficient to characterize the
complexities of treating these older patients.
Participants
Patients with newly diagnosed primary or secondary
MDS or AML, according to the 2008 revised World
Health Organization criteria [6], or ICUS as defined by
Valent et al. [8] are eligible for inclusion. Patients do not
have to receive treatment to participate. Disease diagnosis
must (1) be confirmed by independent central eligibility
review of clinical diagnostic reports of bone marrow aspi-
rates and biopsies, cytogenetic analyses, molecular testing,
and laboratory results and (2) occur ≤ 60 days prior to giv-
ing informed consent. Cohort assignment, including IPSS
risk for patients with MDS, will be confirmed by central
review. Reports of bone marrow aspirates or biopsies must
be available for patients with MDS or ICUS but not those
with AML if the laboratory results show ≥ 20 % blasts in
the peripheral blood. Patients with MDS or ICUS
must be ≥ 18 years of age, and patients with AML
must be ≥ 55 years of age. Patients with suspected or
proven acute promyelocytic leukemia are excluded be-
cause these patients benefit from treatment with dis-
tinct regimens that lead to favorable outcomes [21].
Patients with MDS or ICUS previously treated with
disease-modifying agents, including prior cytotoxic
agents for MDS (drugs for other cancers are allowed),
azacitidine, decitabine, lenalidomide, or targeted therapies
(eg, FLT3 inhibitors), are excluded. Patients with AML
can have initiated treatment with active agents within
14 days prior to providing informed consent. Prior
use of supportive care, such as transfusions, antibiotics,
iron chelators, erythropoiesis-stimulating agents or other
hematopoietic growth factors, and tumor lysis prophylaxis
is allowed. Patients with AML secondary to MDS could
have received prior therapy with active agents for treat-
ment of MDS. All patients must also be willing and able
to complete the enrollment and follow-up PRO instru-
ments in English or Spanish.
Data collection
Patient data will be entered into the electronic data cap-
ture (EDC) system at screening, enrollment (ie, baseline),
and approximately quarterly intervals throughout the dur-
ation of a patient’s participation. All decisions regarding
patient care (treatment, response assessment, etc.) will be
determined by the study clinician, as the disease registry is
non-interventional. The EDC will capture clinical out-
comes, and patients will be followed for 8 years or until
early study termination, patient withdrawal, or death. For
patients with MDS treated with supportive care alone, the
median survival ranges from 0.4 years in the high-risk
IPSS group to 5.7 years in the low-risk IPSS group [28].
For patients with AML, the 5-year survival rate is 27 %,
whereas for older patients (75–84 years), the 1-year sur-
vival is 15 % [12, 29]. Thus, the 8-year follow-up period is
an adequate length of time to acquire robust data on both
the short- and long-term outcomes of patients with MDS,
ICUS, and AML. Follow-up will continue regardless of
whether patients remain on or discontinue treatment. The
total study duration is approximately 11 years, including a
3-year screening and enrollment period and an 8-year
follow-up period.
Information to be captured by the disease registry in-
cludes baseline characteristics, comorbidities, frailty
evaluations, diagnostic testing results, treatment, clinical
outcomes, HEOR, and HRQOL, as described in Table 1.
Patient-reported HRQOL data will be collected using
2 instruments: the Functional Assessment of Cancer
Therapy-Anemia (FACT-An), which assesses physical, so-
cial, family, emotional, and functional well-being, and fa-
tigue- and anemia-related concerns [30] and the EuroQol
Group 5-dimension, 3-level questionnaire (EQ-5D-3 L),
which assesses mobility, self-care, usual activities, pain
and discomfort, anxiety, depression, and overall health
status [31]. All clinical outcomes will be assessed by
the treating physician as would occur in routine clinical
practice (Table 2) and captured using electronic case
report forms.
Data quality
Certain aspects of the disease registry were designed to
mitigate potential biases that could affect data quality.
To control for selection bias, all consecutive patients at
each site who are diagnosed with MDS, ICUS, or AML
and who are potentially eligible for the disease registry
will be presented with the option of enrolling, until ac-
crual is met. To ensure high-quality data collection, each
site will participate in training specific to registries via
investigator meetings, teleconferences, or webinars, and
a site initiation visit via teleconference or webinar with
United BioSource Corporation (UBC). Ongoing site sup-
port and continuing education will be provided through-
out the duration of the study. Information bias will be
prevented through the proper handling of missing data
by the EDC system. A major advantage of using an EDC
system for data collection is that it allows real-time,
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remote data quality control through edit checks and data
queries that are automated based on validation rules
programmed in advance. This eliminates the need for
on-site monitoring, as the programmed validation rules
will obtain immediate feedback if data are missing or un-
clear. For example, data fields will be programmed in a
way that prevents leaving an entry blank, and error mes-
sages will be generated in real time if values entered out-
side of the preset range are detected.
Biomarker tissue substudy
MDS and AML are known to have a complex genetic
architecture [2, 6, 10, 21]. A number of clonal abnormalities
are known to have prognostic import in MDS and AML
and are incorporated into assessments of disease risk [19,
21]. However, there are many more for which prognostic or
predictive impact remain to be determined or conclusively
validated. For example, more than 40 recurrent somatic
mutations are described in MDS and are organized into a
number of biological pathways involving pre-mRNA
splicing, epigenetic patterning (including DNA methy-
lation, which influences gene expression), chromatin
conformation, and genome stability [2, 10]. In up to 40 %
of patients with ICUS, MDS-associated genetic mutations
have been observed, but no data exist regarding prognos-
tic implications, and the extent to which these patients
overlap with MDS is unclear, since 10 % of patients aged >
70 years with normal blood counts also have MDS-
associated genetic mutations and are said to have CHIP
[9–11].
Therefore, an optional, non-interventional, correlative
substudy will be conducted to explore the relationship be-
tween karyotypes, molecular markers, and clinical out-
comes. Participating patients will provide a bone marrow
sample, collected as part of routine medical care at screen-
ing or later if done prior to active therapy initiation, as
well as peripheral blood samples collected at screening
(also prior to active therapy initiation) and at clinically
relevant post-baseline time points. To aid in the distinc-
tion of somatic variants from germline polymorphisms,
oral epithelial cells will be collected. A best effort will
be made to collect all of these samples from study sites
participating in the biomarker tissue substudy. All partici-
pating sites will follow a study-specific laboratory manual
to collect and ship the samples to Genoptix, a Clinical
Laboratory Improvement Amendments (CLIA)-certified
laboratory. The substudy objectives are to:
1. Evaluate DNA mutations for further prognostic
classification of MDS and AML subtypes, and
evaluate their potential impact on treatment options;
Table 2 Key clinical outcomes captured by the Connect MDS/
AML Disease Registry









• Complete remission marrow
• Partial remission marrow






• Progression/relapse after hematologic
improvement
• Cytogenetic response
Safety • Type, frequency, and duration and outcomes of SAEs
• Onset of SPM and other events of interest
• AEs that lead to treatment discontinuation
• Deaths/reasons for deaths
AE adverse event, AML acute myeloid leukemia, SAE serious adverse event,
SPM, second primary malignancy








• Patient demographics and medical history
• Prior malignancies
• ECOG performance status
• Clinical frailty scale
• Adult comorbidity evaluation (ACE-27)
• Current and concomitant medications
Diagnostic
patterns
• Central eligibility review results
• Hematology/peripheral blood laboratory results
• Bone marrow biopsies/aspirate reports
• FISH analysis, flow cytometry, molecular analysis reports




• Physician’s therapeutic objective
• MDS and AML therapy, including supportive care
• Changes in MDS and AML therapies
• Transfusion information
• Transplant eligibility and history
• Select concomitant medications
Clinical
outcomes





• Events of interestb
HEOR and
HRQOL
• Hospitalization (number, length of stay, treatments
used, etc.)
• Patient-reported HRQOL instruments
AE adverse event, AML acute myeloid leukemia, CNS central nervous system,
ECOG Eastern Cooperative Oncology Group, FISH fluorescence in situ
hybridization, HEOR health economics and outcomes research, HRQOL health-
related quality of life, ICUS idiopathic cytopenia of undetermined significance,
IPSS International Prognostic Scoring System, MDS myelodysplastic syndromes
aFor MDS, IPSS is used for prognostication. For AML, both cytogenetic and
molecular data are used for risk assessment
bMDS: second primary malignancies; AML: extramedullary progression
(including CNS) and second primary malignancies; ICUS: progression to MDS
or AML
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2. Summarize clinical status of patients with and
without mutations;
3. Analyze the correlation between mutations and
allele burden in bone marrow and peripheral
blood samples.
Data analysis
The data generated from the disease registry will describe
diagnostic patterns, treatment decisions and responses,
therapeutic regimens, and associated clinical, HRQOL,
and HEOR outcomes. Routine clinical practice patterns
will be compared with existing management guidelines
(ie, NCCN). The disease registry will be managed by UBC
with oversight by the MDS and AML SSCs. Celgene, in
conjunction with the SSCs, will establish a uniform pro-
cedure for analyzing, publishing, and disseminating find-
ings from the disease registry. Data from all study centers
will be combined, and all analyses will be performed
within the disease cohorts. The final analyses will be
performed by cohort once all patients within a cohort
have completed the study. Descriptive summary statistics
will be calculated for the majority of data collected, in-
cluding demographics, diagnosis and IPSS risk classifi-
cation, baseline characteristics, medical history, prior
therapy, concomitant medications, treatment regimens
and exposure, safety outcomes, and HEOR. Treatment-
effectiveness outcomes, including response rates, disease
progression, overall survival, other clinical outcomes, and
HRQOL will also be summarized. Potential confounders
will be considered, such as patient’s age group, type of en-
rolling institution (academic vs community), geographic
location, and other demographic and baseline factors, par-
ticularly those that represent patient’s medical history and
socioeconomic background. All statistical analyses will be
conducted using SAS version 9.2 or higher. Statistical test-
ing will be conducted at the α = 0.05 (2-sided) significance
level, and 2-sided P-values and confidence intervals will
be reported. Specialized methods, such as propensity score
modeling, will be utilized to compensate for expected
biases within these nonrandomized groups.
Fig. 2 Locations of accepted study sites. As of November 30, 2015, there were 169 accepted study sites in the United States and Puerto Rico,
including academic, community, and government sites
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Status of the registry
The first patient was enrolled in the disease registry on
December 12, 2013. As of November 30, 2015, enroll-
ment is 306 patients. There are currently 104 patients
enrolled in the IPSS lower-risk MDS cohort (10 patients
with del(5q) and 94 patients without del(5q)), 80 patients
in the IPSS higher-risk MDS cohort, 0 patients in the
ICUS cohort, and 121 patients in the AML cohort.
There are currently 169 accepted study sites and 149 ac-
tivated sites (Fig. 2).
Discussion
For patients with MDS and AML, key variables affecting
disease outcomes and survival, such as diagnostic trends,
prognostic characterization, treatment patterns, and PROs,
are inadequately documented outside of clinical trials. Even
less is understood about patients with ICUS due to the
recent definition of this population and its heterogeneity.
As a result, decisions about treatment and management
of patients with MDS, ICUS, and AML are complex,
challenging, and complicated by elderly age, high fre-
quency of comorbid conditions, and poor performance
status or HRQOL [5, 11, 24]. To better understand the
epidemiology, disease course, and long-term outcomes,
this first prospective disease registry of patients with
MDS, ICUS, or AML has been designed and initiated
to capture longitudinal data for a cohort of patients
within a single database.
The Connect MDS/AML Disease Registry represents
an opportunity to synthesize information from several
domains, including clinical parameters, diagnostic prac-
tices, prognostic classifications treatments patterns, treat-
ment outcomes, and molecular data in a prospective
fashion. The inclusion of data from such varied domains
will contribute to a large, rich database for future analyses.
Results may provide new insights into diagnostic patterns,
treatment regimens, and treatment sequencing, as well as
how these are associated with clinical outcomes in patients
with MDS, ICUS, or AML in the United States who are
treated outside the context of a clinical trial. The results
will also facilitate evaluation of HRQOL and HEOR out-
comes that may be associated with current treatment regi-
mens in routine clinical practice in the United States.
Correlative analyses using molecular data will increase the
understanding of MDS, ICUS, and AML and may reveal
novel prognostic and predictive biomarkers for these
diseases and offer the opportunity to validate newly
discovered biomarkers. As a recent update of the IPSS-R
incorporates mutation data, it will be important to analyze
the impact of these specific prognostic mutations on MDS
cohorts included this registry. Given the ever-increasing
information on molecular mutations in MDS and AML,
this study will aid in describing mutations in the context
of patient diagnosis, treatment, and outcomes.
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